terameprocol has been researched along with Brain Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Desideri, S; Grossman, SA; Mikkelsen, T; Peereboom, D; Rosenfeld, MR; Supko, JG; Ye, X | 1 |
| Borges, KS; Carlotti, CG; Castro-Gamero, AM; de Oliveira, HF; de Paula Gomes Queiroz, R; Fujinami, MM; Moreno, DA; Scrideli, CA; Suazo, VK; Tone, LG | 1 |
1 trial(s) available for terameprocol and Brain Neoplasms
| Article | Year |
|---|---|
Phase I study of terameprocol in patients with recurrent high-grade glioma.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Female; Glioma; Humans; Male; Masoprocol; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome | 2012 |
1 other study(ies) available for terameprocol and Brain Neoplasms
| Article | Year |
|---|---|
Tetra-O-methyl nordihydroguaiaretic acid, an inhibitor of Sp1-mediated survivin transcription, induces apoptosis and acts synergistically with chemo-radiotherapy in glioblastoma cells.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Dose-Response Relationship, Drug; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Inhibitor of Apoptosis Proteins; Inhibitory Concentration 50; Male; Masoprocol; Mitotic Index; Radiation-Sensitizing Agents; RNA Splicing; RNA, Messenger; Sp1 Transcription Factor; Survivin; Temozolomide; Transcription, Genetic | 2013 |